Plant Summary
Plant Information
TCMBank_ID: | TCMBANKHE004162 |
YEM_ID: | YEM-17 |
ID: | TCMBANKHE004162/YEM-17 |
植物拉丁名: |
|
功能与主治: | To resolve toxin, clear heat and calm liver, anticancer./Hypertension, swelling toxin of welling abscess and sore, scalds. |
药用植物名: | 长春花 |
药名: | 长春花 |
来源: | 云南民族药物志：第一卷 |
药用部位: | whole herb |
临床特征: | 1. Vinblastine and vincristine are the active componens which inhibit leukemia and other cancers. They interfere with mitosis and inhibit synthesis of purine, DNA and RNA. 2. Lowering blood pressure and the level of blood sugar. 3. Diuretic. 4. Vinblastin |
TCM_ID_id: | 5384 |
TCMSP_id: | 911 |
植物对应的化合物
| 化合物ID | 化合物名 | 别名 | 分子式 | 分子质量 | Smiles |
|---|
| TCMBANKIN000033 | vincamine | C21H26N2O3 | 354.44 | CCC12CCCN3C1C4=C(CC3)C5=CC=CC=C5N4C(C2)(C(=O)OC)O | |
| TCMBANKIN000113 | vinblastine | vinblastine | C46H58N4O9 | 810.97 | CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O |
| TCMBANKIN000149 | persicarin | C16H12O10S | 396.3 g/mol | COC1=C(C=CC(=C1)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)OS(=O)(=O)O)O | |
| TCMBANKIN000826 | 4- 乙基- 芍药苷 | ||||
| TCMBANKIN001484 | leurosivine | 0 | |||
| TCMBANKIN002164 | Morning glory pigment | ||||
| TCMBANKIN002568 | coronarin a | C20H28O2 | 300.4 g/mol | CC1(CCCC2(C1CC(C(=C)C2C=CC3=COC=C3)O)C)C | |
| TCMBANKIN003512 | leurocristine | leurocris-tine | C46H58N4O14S | 923 g/mol | CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O |
| TCMBANKIN003608 | serpentine | C21H21N2O3+ | 349.4 g/mol | CC1C2C[N+]3=C(CC2C(=CO1)C(=O)OC)C4=C(C=C3)C5=CC=CC=C5N4 | |
| TCMBANKIN004618 | pericyclivine | C20H22N2O2 | 322.4 g/mol | CC=C1CN2C3CC1C(C2CC4=C3NC5=CC=CC=C45)C(=O)OC | |
| TCMBANKIN004809 | alstonine | C21H21ClN2O3 | 0 | CC1C2CN3C=CC4=C5C=CC=CC5=NC4=C3CC2C(=CO1)C(=O)OC.Cl | |
| TCMBANKIN005958 | mthyljasmonate | C14H22O3 | CCC=CCC1(C(CCC1=O)CC(=O)OC)C | ||
| TCMBANKIN006444 | pleniradin | C15H20O4 | 264.32 g/mol | CC1=CC2C(CC3C1C(CC3(C)O)O)C(=C)C(=O)O2 | |
| TCMBANKIN006726 | taccalonolide e | C34H44O12 | 644.7 g/mol | CC1C=C2C(C3C1C4(C(CC5C(C4C3OC(=O)C)C(C(=O)C6C5(C(C7C(C6)O7)OC(=O)C)C)O)OC(=O)C)C)(C(C(=O)O2)(C)O)C | |
| TCMBANKIN007579 | moellendorffiline | C26H20O10 | 492.4 g/mol | COC1=C(C2=C(C=CO2)C3=C1C4C5C(C4C(=O)O3)C(=O)OC6=C5C(=C(C7=C6C=CO7)OC)OC)OC | |
| TCMBANKIN008765 | lochneridine | C20H24N2O3 | 340.4 g/mol | CCC1(CN2CCC34C2CC1C(=C3NC5=CC=CC=C45)C(=O)OC)O | |
| TCMBANKIN008852 | isoleurosine | C46H58N4O8 | 795 g/mol | CCC1CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC | |
| TCMBANKIN008914 | catharanthusopimaranoside A | ||||
| TCMBANKIN009317 | vindolin | C25H32N2O6 | 456.5 g/mol | CCC12C=CCN3C1C4(CC3)C(C(C2OC(=O)C)(C(=O)OC)O)N(C5=C4C=CC(=C5)OC)C | |
| TCMBANKIN009362 | Coronaridine | coronaridine; coronaridine | C21H26N2O2 | 338.44 | CCC1CC2CC3(C1N(C2)CCC4=C3NC5=CC=CC=C45)C(=O)OC |
| TCMBANKIN009689 | gomaline | C30H42N4O2 | 490.7 g/mol | CN1CCCN(C(=O)CC1C2=CC=CC=C2)CCCCN3CCCN(C(CC3=O)C4=CC=CC=C4)C | |
| TCMBANKIN010423 | vinamidine | C46H56N4O10 | 825 g/mol | CCC(=O)CC1CC(C2=C(CCN(C1)C=O)C3=CC=CC=C3N2)(C4=C(C=C5C(=C4)C67CCN8C6C(C=CC8)(C(C(C7N5C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC | |
| TCMBANKIN010456 | dihydrovindolinine | C21H26N2O2 | 338.4 g/mol | CC1C23CCCN4C2C5(C1(C(C3)C(=O)OC)NC6=CC=CC=C65)CC4 | |
| TCMBANKIN011789 | 16-Ep-i19-S-vindolinine-N-oxide | C21H24N2O3 | 352.4 g/mol | CC1C23CC(C14C5(C2[N+](CC5)(CC=C3)[O-])C6=CC=CC=C6N4)C(=O)OC | |
| TCMBANKIN012091 | alpha-amyrin acetate | α-amyrin acetate; alpha-Amyrin acetate | C32H52O2 | 468.75 | CC1CCC2(CCC3(C(=CCC4C3(CCC5C4(CCC(C5(C)C)OC(=O)C)C)C)C2C1C)C)C |
| TCMBANKIN012212 | dihydrositsirikine | C21H28N2O3 | CCC1CN2CCC3=C(C2CC1C(CO)C(=O)OC)NC4=CC=CC=C34 | ||
| TCMBANKIN012461 | gomezine | C18H20N2 | 264.4 g/mol | CC=C1CN2CCC1C(=C)C3=C(C2)C4=CC=CC=C4N3 | |
| TCMBANKIN012636 | tetrahydroalstonine | Tetrahydroalstonine; C11682; 6474-90-4; Alstonine, 3,4,5,6-tetrahydro- (8CI); 4-27-00-07926 (Beilstein Handbook Reference); NCGC00163632-01; Prestwick1_000593; PDSP2_001642; Prestwick2_000593; SPBio_002685; NSC 72115; Alstonine, 3,4,5,6-tetrahydro; 16,17-Didehydro-19-methyloxayohimban-16-carboxylic acid, methyl ester; 4CN-0678; SCHEMBL14095094; BRN 0097270; EINECS 229-331-0; METHYL (15S,16S,20S)-16-METHYL-17-OXA-3,13-DIAZAPENTACYCLO[11.8.0.0(2),(1)?.0?,?.0(1)?,(2)?]HENICOSA-2(10),4,6,8,18-PENTAENE-19-CARBOXYLATE; MFCD00083501; Methyl (19alpha,20alpha)-16,17-didehydro-19-methyloxayohimban-16-carboxylate; Alstonine, 3,4,5,6-tetrahydro-, (3alpha)-; AIDS-003047; Prestwick_462; CHEBI:95146; HMS1569H08; Prestwick0_000593; AKOS032948288; Oxayohimban-16-carboxylic acid, 16,17-didehydro-19-methyl-, methyl ester, (19-alpha,20-alpha)-; AIDS003047 | C21H25N2O3+ | 353.4 g/mol | CC1C2C[NH+]3CCC4=C(C3CC2C(=CO1)C(=O)OC)NC5=CC=CC=C45 |
| TCMBANKIN012968 | 2α-acetoxy-2'β-deacetyl-1-hydroxyaustrospi-catine | C41H55NO14 | |||
| TCMBANKIN013477 | Perlatolic acid | 2-hydroxy-4-[(2-hydroxy-4-methoxy-6-pentylphenyl)-oxomethoxy]-6-pentylbenzoic acid; NCI60_015815; 529-47-5; 2-Hydroxy-4-((2-hydroxy-4-methoxy-6-pentylbenzoyl)oxy)-6-pentylbenzoic acid; perlatolicacid; 2-amyl-4-(2-amyl-6-hydroxy-4-methoxy-benzoyl)oxy-6-hydroxy-benzoic acid; 2-hydroxy-4-(2-hydroxy-4-methoxy-6-pentyl-phenyl)carbonyloxy-6-pentyl-benzoic acid; Perlatolinic acid; beta-Resorcylic acid, 6-pentyl-, 4-(2-hydroxy-6-pentyl-p-anisate); perlatolic acid; AIDS138684; NSC646002; AIDS-138684; 2-hydroxy-4-(2-hydroxy-4-methoxy-6-pentyl-benzoyl)oxy-6-pentyl-benzoic acid; 2-hydroxy-4-(2-hydroxy-4-methoxy-6-pentylbenzoyl)oxy-6-pentylbenzoic acid | C25H32O7 | 444.52 | CCCCCC1=C(C(=CC(=C1)OC)O)C(=O)OC2=CC(=C(C(=C2)O)C(=O)O)CCCCC |
| TCMBANKIN013551 | Rosin prime 3-O- [6-O-(α- rhamnose-yl)[beta]-galactosidase] | ||||
| TCMBANKIN013775 | lochnerinine | C22H26N2O4 | 382.5 g/mol | CCC12CC(=C3C4(C1N(CC4)CC5C2O5)C6=C(N3)C=C(C=C6)OC)C(=O)OC | |
| TCMBANKIN014325 | vincoline | C21H24N2O4 | 368.4 g/mol | CC1C23CC(O1)(C4(C5(C2N(CC5)CC=C3)C6=CC=CC=C6N4)O)C(=O)OC | |
| TCMBANKIN014361 | desactoxy VLB | ||||
| TCMBANKIN015646 | n-hentetracont-36-en-5β-ol | ||||
| TCMBANKIN016009 | leurosidine vrs | 0 | |||
| TCMBANKIN016103 | catharanthine | catharan-thine | C21H24N2O2 | 336.4 g/mol | CCC1=CC2CC3(C1N(C2)CCC4=C3NC5=CC=CC=C45)C(=O)OC |
| TCMBANKIN016658 | lochnericine | Lochnericine; Aspidospermidine-3-carboxylic acid, 2,3-didehydro-6,7-epoxy-, methyl ester, (5alpha,6alpha,7alpha,12R,19alpha)-; SCHEMBL6535297; (5alpha,6alpha,7alpha,12beta,19alpha)-2,3-Didehydro-6,7-epoxyaspidospermidine-3-carboxylic acid methyl ester; Lochnericine, (-)-; CHEMBL2011514; (-)-Lochnericine; Lochnericine [MI]; UNII-WY97J4B4AM; 72058-36-7; WY97J4B4AM | C21H24N2O3 | 352.4 g/mol | CCC12CC(=C3C4(C1N(CC4)CC5C2O5)C6=CC=CC=C6N3)C(=O)OC |
| TCMBANKIN016883 | leurosine vlr | 0 | |||
| TCMBANKIN016971 | 3,4-mimethoxytoluene | ||||
| TCMBANKIN017543 | leurocolombine | 0 | |||
| TCMBANKIN017808 | serpentinine | C33H40N2O9 | 608.68 | CC=C1CN2CCC3=C(C2CC1C(CC4=C[N+]5=C(CC6C(C5)C(OC=C6C(=O)OC)C)C7=C4C8=CC=CC=C8N7)C(=O)OC)NC9=CC=CC=C39 | |
| TCMBANKIN018001 | dehydrologanin | METHYL 7-METHYL-6-OXO-1-{[(2S,3R,4S,5S,6R)-3,4,5-TRIHYDROXY-6-(HYDROXYMETHYL)OXAN-2-YL]OXY}-1H,4AH,5H,7H,7AH-CYCLOPENTA[C]PYRAN-4-CARBOXYLATE | C17H24O10 | 388.4 g/mol | CC1C2C(CC1=O)C(=COC2OC3C(C(C(C(O3)CO)O)O)O)C(=O)OC |
| TCMBANKIN018290 | mitraphylline | C21H24N2O4 | 368.4 g/mol | CC1C2CN3CCC4(C3CC2C(=CO1)C(=O)OC)C5=CC=CC=C5NC4=O | |
| TCMBANKIN020081 | methylvingramine | C47H58N4O8 | 807 g/mol | CC=C1CN2CCC34C2(CCC1C3C(=O)OC)N(C5=C(C(=C(C=C45)OC)C6=C(C=C7C(=C6)C8=C(N7C)C9C1C(C8C(=O)OC)C(CN9C(=O)C(C)C)C(O1)C)OC)C)C | |
| TCMBANKIN020926 | n-pentadecanyl octa一dec一19-en-oate | ||||
| TCMBANKIN020974 | 7-O-Methyl anthocyanin3-O- [6-O-(α- rhamnose-yl)[beta]-galactosidase] | ||||
| TCMBANKIN021625 | Primula pigment | ||||
| TCMBANKIN021812 | Dihydrosolidagenone | (4aS)-4-[2-(furan-3-yl)ethyl]-4-hydroxy-3,4a,8,8-tetramethyl-2,3,5,6,7,8a-hexahydronaphthalen-1-one; AC1NSULK; dihydrosolidagenone | C20H30O3 | 318.4 g/mol | CC1CC(=O)C2C(CCCC2(C1(CCC3=COC=C3)O)C)(C)C |
| TCMBANKIN023308 | vingramine | C46H56N4O8 | 793 g/mol | CC=C1CN2CCC34C2(CCC1C3C(=O)OC)NC5=C(C(=C(C=C45)OC)C6=C(C=C7C(=C6)C8=C(N7C)C9C1C(C8C(=O)OC)C(CN9C(=O)C(C)C)C(O1)C)OC)C | |
| TCMBANKIN023358 | desacetylvindoline | desacetyl-vindoline | C23H30N2O5 | 414.5 g/mol | CCC12C=CCN3C1C4(CC3)C(C(C2O)(C(=O)OC)O)N(C5=C4C=CC(=C5)OC)C |
| TCMBANKIN023655 | delphatine | C26H43NO7 | 481.6 g/mol | CCN1CC2(CCC(C34C2C(C(C31)(C5(CC(C6CC4C5C6OC)OC)O)O)OC)OC)COC | |
| TCMBANKIN024098 | 3-0-Caffeoylquinic acid | ||||
| TCMBANKIN025841 | catharine | C46H54N4O10 | 822.9 g/mol | CCC1=CN(CCC2=C(C(CC(=O)C1)(C3=C(C=C4C(=C3)C56CCN7C5C(C=CC7)(C(C(C6N4C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)NC8=CC=CC=C28)C=O | |
| TCMBANKIN026607 | sitsirikine | methyl 2-(3-ethenyl-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizin-2-yl)-3-hydroxypropanoate; AC1NT0G0 | C21H26N2O3 | 354.4 g/mol | COC(=O)C(CO)C1CC2C3=C(CCN2CC1C=C)C4=CC=CC=C4N3 |
| TCMBANKIN027330 | rosmaricine | C20H27NO4 | 345.4 g/mol | CC(C)C1=C(C(=C2C(=C1)C(C3C4C2(CCCC4(C)C)C(=O)O3)N)O)O | |
| TCMBANKIN027621 | leurosine | C46H56N4O9 | 809 g/mol | CCC12CN3CCC4=C(C(CC(C3)C1O2)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)NC1=CC=CC=C41 | |
| TCMBANKIN027842 | vincristine | AC-20336; 57-22-7; AKOS015965501 | C46H56N4O10 | 825 g/mol | CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O |
| TCMBANKIN028164 | akuammicine | UNII-RG055O00BG; Curan-17-oic acid, 2,16,19,20-tetradehydro-, methyl ester, (19E)-; Methyl (19E)-2,16,19,20-tetradehydrocuran-17-oate; 639-43-0; Akuammicine; RG055O00BG; CHEBI:70499 | C20H23N2O2+ | 323.4 g/mol | CC=C1C[NH+]2CCC34C2CC1C(=C3NC5=CC=CC=C45)C(=O)OC |
| TCMBANKIN028180 | reserpine | C33H40N2O9 | 608.7 g/mol | COC1C(CC2CN3CCC4=C(C3CC2C1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC | |
| TCMBANKIN028254 | vincorodine | ||||
| TCMBANKIN029508 | tabersonine | C21H25N2O2+ | 337.4 g/mol | CCC12CC(=C3C4(C1[NH+](CC4)CC=C2)C5=CC=CC=C5N3)C(=O)OC | |
| TCMBANKIN029925 | lochnerine | C20H24N2O2 | 324.4 g/mol | CC=C1CN2C3CC1C(C2CC4=C3NC5=C4C=C(C=C5)OC)CO | |
| TCMBANKIN030877 | perivine | C20H22N2O3 | 338.4 g/mol | CC=C1CNC2CC3=C(C(=O)CC1C2C(=O)OC)NC4=CC=CC=C34 | |
| TCMBANKIN031437 | Quercetin-3-O-(2,6- two-O-α-L- rhamnose group-β-D- galactoside) | ||||
| TCMBANKIN031577 | desacetyl VLB | C44H58N4O12S | CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)O)CC)OC)C(=O)OC)O.OS(=O)(=O)O | ||
| TCMBANKIN031873 | catharosine | C22H28N2O4 | 384.5 g/mol | CCC12C=CCN3C1C4(CC3)C(C(C2O)(C(=O)OC)O)N(C5=CC=CC=C45)C | |
| TCMBANKIN032231 | vincathicine | C46H56N4O9 | 809 g/mol | CCC1(CN2CCC34C1C(C2)CC(C3=NC5=CC=CC=C45)(C6=C(C=C7C(=C6)C89CCN1C8C(C=CC1)(C(C(C9N7C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O | |
| TCMBANKIN032329 | securinine | securinine | C13H15NO2 | 217.26 | C1CCN2C(C1)C34CC2C=CC3=CC(=O)O4 |
| TCMBANKIN032541 | catharanthusopimaranoside B | ||||
| TCMBANKIN032709 | 5一O一deca一2E,4E,6E-trienoyl一3,20一O一diacetylingenol | ||||
| TCMBANKIN032791 | Kaempferol-3-O-(2,6- two-O-α-L- rhamnose group-β-D- galactosidase) | ||||
| TCMBANKIN033003 | N-demethyl VLB | ||||
| TCMBANKIN033235 | Inositol-b | inositol-b | C6H12O6 | 180.16 | |
| TCMBANKIN033804 | cleavamine | cleav-amine | C19H24N2 | 280.4 g/mol | CCC1=CC2CCC3=C(CCN(C2)C1)C4=CC=CC=C4N3 |
| TCMBANKIN033958 | rovidine | 0 | |||
| TCMBANKIN034431 | vindorosine | C24H30N2O5 | 426.5 g/mol | CCC12C=CCN3C1C4(CC3)C(C(C2OC(=O)C)(C(=O)OC)O)N(C5=CC=CC=C45)C | |
| TCMBANKIN035410 | 3一epi一betulinic acid | ||||
| TCMBANKIN036149 | Catharanthamine | catharanthamine | C46H56N4O9 | 808.96 | CCC12CC3CN(C1)CCC4=C(C(C3O2)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)NC1=CC=CC=C41 |
| TCMBANKIN036224 | anhydro VLB | ||||
| TCMBANKIN036264 | vincadioline | C46H58N4O10 | 0 | CCC1(CN2CCC3=C(C(CC(C2)C1O)(C4=C(C=C5C(=C4)C67CCN8C6C(C=CC8)(C(C(C7N5C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)NC9=CC=CC=C39)O | |
| TCMBANKIN036299 | 6,14-dimethoxyforesticine | C26H43NO6 | CCN1CC2(CCC(C34C2C(C(C31)C5(CC(C6CC4C5C6OC)OC)O)OC)OC)COC | ||
| TCMBANKIN036524 | perilal | AOVAKEPXEOVCEW-MGCOHNPYSA-N; AKOS030613877; AK658376; FEMA No. 4312, Z-; Cyclohexanecarboxaldehyde, 4-(1-methylethenyl)-; 1,2-Dihydroperillaldehyde; 1,2-Dihydroperillaldehyde, (E)-; VPH010VHP3; 1,2-Dihydroperillaldehyde, (E)-, and (Z)-; UNII-0RY0P8YIKM; ACMC-20mwy6; 0RY0P8YIKM; UNII-HW6871CJ1V; AK658377; 4-Isopropenyl-cyclohexanecarboxaldehyde; CTK0I8509; SCHEMBL4275139; AOVAKEPXEOVCEW-UHFFFAOYSA-N; (1alpha,4alpha)-p-Mentha-8-ene-7-al; 22451-50-9; AOVAKEPXEOVCEW-AOOOYVTPSA-N; FEMA No. 4312, E-; 4-(Prop-1-en-2-yl)cyclohexanecarbaldehyde; Cyclohexanecarboxaldehyde, 4-isopropenyl-, cis-; trans-1,2-Dihydroperillaldehyde; (1alpha,4beta)-p-Mentha-8-ene-7-al; 137886-38-5; UNII-VPH010VHP3; 1,2-Dihydroperillaldehyde, (Z)-; 4-prop-1-en-2-ylcyclohexane-1-carbaldehyde; Cyclohexanecarboxaldehyde, 4-isopropenyl-, trans-; trans-Dihydroperillaldehyde; HW6871CJ1V; CTK0F3390; cis-Dihydroperillaldehyde; FEMA No. 4312; Trans-4-(prop-1-en-2-yl)cyclohexanecarbaldehyde; UNII-HW6871CJ1V component AOVAKEPXEOVCEW-MGCOHNPYSA-N; AC1LB1NM; (+/-)-cis- and trans-1,2-Dihydroperillaldehyde [FIFH]; 4-(PROP-1-EN-2-YL)CYCLOHEXANE-1-CARBALDEHYDE; AKOS030613878; UNII-HW6871CJ1V component AOVAKEPXEOVCEW-AOOOYVTPSA-N; 22451-49-6; Cyclohexanecarboxaldehyde, 4-(1-methylethenyl)-, trans-; SCHEMBL14495583; (+/-)-cis- and trans-1,2-Dihydroperillaldehyde; cis-1,2-Dihydroperillaldehyde; Cyclohexanecarboxaldehyde, 4-(1-methylethenyl)-, cis- | C10H16O | 152.23 g/mol | CC(=C)C1CCC(CC1)C=O |
| TCMBANKIN037952 | Isosophaocarpine | C15H22N2O | 246.348 | C1([H])=C([H])C([H])([H])[C@@]([H])([C@]2([H])[C@]([H])(N(C([H])([H])C([H])([H])C3([H])[H])C([H])([H])C([H])([H])C2([H])[H])[C@]3([H])C4([H])[H])N4C1=O | |
| TCMBANKIN038012 | vineridine | C22H26N2O5 | 398.5 g/mol | CC1C2CN3CCC4(C3CC2C(=CO1)C(=O)OC)C5=C(C=C(C=C5)OC)NC4=O | |
| TCMBANKIN038017 | Pseudovincaleukoblastine diol | ||||
| TCMBANKIN038813 | Leurocolumbine | ||||
| TCMBANKIN039495 | vindolinine-n-oxide | vindolininen-oxide | C21H25N2O3 | ||
| TCMBANKIN039926 | Pleiocarpamine | 322.4 g/mol | |||
| TCMBANKIN040785 | Vindoline | 456.5 g/mol | |||
| TCMBANKIN040955 | 4-deacetyl-11(15→1)-abeo-baccatin vi | C35H44O13 | |||
| TCMBANKIN041262 | isoimperatorin | AJ-19023; Oprea1_655950; 7H-Furo[3,2-g][1]benzopyran-7-one,4-[(3-methyl-2-buten-1-yl)oxy]-; NCGC00180809-02!4-(3-methylbut-2-enoxy)furo[3,2-g]chromen-7-one; Isoimperatorin, analytical standard; 4-[(3-methylbut-2-en-1-yl)oxy]-7h-furo[3,2-g]chromen-7-one; MCULE-5468436292; Iso-imperatorin; UNII-0ZMV066080; BDBM50242377; ZB010260; BG00617053; BRD-K40367461-001-01-0; ZINC00296185; ACN-035226; HMS2268M21; CS-5801; ACon1_000176; MLS001048978; MLS000574919; API0003033; Q-100533; Oprea1_630212; 4-(3-methylbut-2-enoxy)-7-furo[3,2-g]chromenone; Iso Imperatorin; isoimperatorin ; 4-[(3-METHYLBUT-2-EN-1-YL)OXY]FURO[3,2-G]CHROMEN-7-ONE; AN-8401; CTK4J0732; I06-0434; C16976; 7,4-[(3-methyl-2-butenyl)oxy]-7H-furo[3,2-g]-1-benzopyran-7-one; AB0019796; 7H-Furo[3,2-g][1]benzopyran-7-one, 4-((3-methyl-2-butenyl)oxy)-; AIDS-071126; SCHEMBL15090959; IGWDEVSBEKYORK-UHFFFAOYSA-N; TR-031434; 482I451; NCGC00180809-01; 482-45-1; DTXSID60197460; 7H-Furo[3,2-g][1]benzopyran-7-one, 4-[(3-methyl-2-butenyl)oxy]-; 4-((3-methylbut-2-en-1-yl)oxy)-7H-furo[3,2-g]chromen-7-one; AK-23906; Isoimperatorin; AC1Q6AY9; KS-00000NN4; MFCD00272155; 0ZMV066080; AC-8047; AX8008744; SMR000156243; CHEMBL448060; HY-N0286; CHEBI:66071; KB-294187; FT-0656369; 10-[(3-methyl-2-butenyl)oxy]-7H-furo[3,2-g][1] benzopyran-7-one; STOCK1N-27740; ZINC296185; N1746; ST24047429; 4-[(3-Methyl-2-butenyl)oxy]-7H-furo[3,2-g]chromen-7-one #; MolPort-001-740-269; 7H-Furo(3,2-g)(1)benzopyran-7-one, 4-((3-methyl-2-butenyl)oxy)-; CI0035; V0302; 7H-Furo[3,2-g][1]benzopyran-7-one,4-[(3-methyl-2-butenyl)oxy]-; AIDS071126; 4-(3-methylbut-2-enoxy)furo[3,2-g]chromen-7-one; AKOS015895143; 4-(3-Methyl-but-2-enyloxy-furo[3,2-g]chromen-7-one; MEGxp0_000090; AC1L28ZP | C17H16O3 | 268.307 | c12c(c([H])c([H])o1)c(C([H])([H])\C([H])=C(/C([H])([H])[H])\C([H])([H])[H])c3c(OC(=C([H])[H])C([H])=C3[H])c2O[H] |
| TCMBANKIN042568 | Vincoside lactam | 498.5 g/mol | |||
| TCMBANKIN042628 | loganin | SDCCGMLS-0066747.P001; KBio2_001983; Spectrum_001503; BSPBio_003350; methyl (1S,4aS,6S,7R,7aS)-6-hydroxy-7-methyl-1-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-1,4a,5,6,7,7a-hexahydrocyclopenta[d]pyran-4-carboxylate; KBio2_004551; KBio1_001603; Loganin; C01433; KBioSS_001983; KBio2_007119; Spectrum2_001637; KBio3_002852; methyl (1S,4aS,6S,7R,7aS)-1-(beta-D-glucopyranosyloxy)-6-hydroxy-7-methyl-1,4a,5,6,7,7a-hexahydrocyclopenta[c]pyran-4-carboxylate; SPBio_001733; Spectrum4_001914; (1S,4aS,6S,7R,7aS)-6-hydroxy-7-methyl-1-[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-2-tetrahydropyranyl]oxy]-1,4a,5,6,7,7a-hexahydrocyclopenta[d]pyran-4-carboxylic acid methyl ester; Methyl (1S-(1alpha,4aalpha,6alpha,7alpha,7aalpha))-1-(beta-D-glucopyranosyloxy)-1,4a,5,6,7,7a-hexahydro-6-hydroxy-7-methylcyclopenta(c)pyran-4-carboxylate; DivK1c_006659; Spectrum5_000628; CHEBI:15771; SpecPlus_000563; (1S,4aS,6S,7R,7aS)-6-hydroxy-7-methyl-1-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-methylol-tetrahydropyran-2-yl]oxy-1,4a,5,6,7,7a-hexahydrocyclopenta[d]pyran-4-carboxylic acid methyl ester; methyl (1S,4aS,6S,7R,7aS)-6-hydroxy-7-methyl-1-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,4a,5,6,7,7a-hexahydrocyclopenta[d]pyran-4-carboxylate; 18524-94-2; EINECS 242-398-0; MEGxp0_000723; SPECTRUM1504066; ACon1_001749; Spectrum3_001875; ZINC03978792; 1-(beta-D-glucopyranosyloxy)-1,4a,5,6,7,7a-hexahydro-6-hydroxy-7-methylcyclopenta[c]pyran-4-carboxylic acid methyl ester; KBioGR_002535; LMPR01020102 | C18H28O10 | 404 | [C@]12([H])[C@@]([H])([C@@]([H])(C([H])([H])[H])[C@@]([H])(O[H])C1([H])[H])[C@]([H])(O[C@]([H])(O[C@@]3(C([H])([H])O[H])C([H])([H])[H])[C@]([H])(O[H])[C@]([H])(O[H])[C@@]3([H])O[H])OC([H])=C2C(OC([H]) ([H])[H])=O |
| TCMBANKIN042739 | deacetoxyvinblastine | C43H54N4O7 | CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(CC(C8N6)(C(=O)OC)O)(C=CC9)CC)OC)C(=O)OC)O | ||
| TCMBANKIN044898 | fluorocarpamine | C20H23N2O3+ | 339.4 g/mol | CC=C1C[NH+]2CCC34C2CC1C(N3C5=CC=CC=C5C4=O)C(=O)OC | |
| TCMBANKIN045375 | isositsirikine | C21H26N2O3 | 354.4 g/mol | CC=C1CN2CCC3=C(C2CC1C(CO)C(=O)OC)NC4=CC=CC=C34 | |
| TCMBANKIN045490 | fluorocarpamine-n-oxide | C20H22N2O4 | 354.4 g/mol | CC=C1C[N+]2(CCC34C2CC1C(N3C5=CC=CC=C5C4=O)C(=O)OC)[O-] | |
| TCMBANKIN046638 | loganoside | SMR000470832; HMS2267G06; SR-01000760596-2; SR-01000760596; AC1L74CC; L0268; NSC606403; Loganoside; methyl (1S,4aS,6S,7R,7aS)-6-hydroxy-7-methyl-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,4a,5,6,7,7a-hexahydrocyclopenta[c]pyran-4-carboxylate; CHEMBL2135791; NSC-606403; MLS000728659 | C17H26O10 | 390.4 g/mol | CC1C(CC2C1C(OC=C2C(=O)OC)OC3C(C(C(C(O3)CO)O)O)O)O |
| TCMBANKIN049173 | catheduline e2 | C38H40N2O11 | 700.7 g/mol | CC1CC(C(C2(C13CC(C(C2OC(=O)C4=CC=CC=C4)OC(=O)C5=CN=CC=C5)C(O3)(C)C)COC(=O)C6=CN=CC=C6)OC(=O)C)OC(=O)C | |
| TCMBANKIN058035 | 1H,3H-Pyrano(3,4-c)pyran-1-one, 5-ethenyl-6-(beta-D-glucopyranosyloxy)-4,4a,5,6-tetrahydro-, (4aS-(4aalpha,5beta,6alpha))-;sweroside | (4aS,5R,6S)-6-[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-2-tetrahydropyranyl]oxy]-5-vinyl-4,4a,5,6-tetrahydro-3H-pyrano[5,4-c]pyran-1-one; ACon1_000233; (4aS,5R,6S)-5-ethenyl-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,4a,5,6-tetrahydro-3H-pyrano[5,4-c]pyran-1-one; 14215-86-2; (4aS,5R,6S)-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-methylol-tetrahydropyran-2-yl]oxy-5-vinyl-4,4a,5,6-tetrahydro-3H-pyrano[5,4-c]pyran-1-one; ACon0_001457; (4aS,5R,6S)-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-5-vinyl-4,4a,5,6-tetrahydro-3H-pyrano[5,4-c]pyran-1-one; MEGxp0_000813 | C16H22O9 | 358.34 | C=CC1C2CCOC(=O)C2=COC1OC3C(C(C(C(O3)CO)O)O)O |
| TCMBANKIN058057 | D-Chiro-Inositol | Chiro-inositol;mesoinositol; Myo-inositol; i-inositol; Inositol-c; scyllo-insitol; Inositol;KS-00001292; TR-022051; BG01505581; MFCD01321249; CTK1C5947; AKOS024318869; INOSITOL (D); Inositene; CHEBI:27374; D-(+)-chiro-Inositol; LT03328768; I-6500; 2H3; (1R,2R,3R,4S,5S,6s)-cyclohexane-1,2,3,4,5,6-hexaol; D07CPO; W-203081; NCGC00178580-01; ZINC103574430; Myoinositol; ZINC100019018; NSC-103959; SCHEMBL13114116; UNII-1VS4X81277; 12513-EP2292610A1; AKOS015912934; NSC25142; Inosite; (1R,2R,3R,4R,5S,6S)-Cyclohexane-1,2,3,4,5,6-hexaol; BG00909558; 1,2,3,4,5,6-Cyclohexanehexol, (cis,cis,cis,trans,cis,trans)- #; BG01505582; NSC-127230; AK307531; Inositol, cis-; NSC 8101; 643-12-9; CHEBI:23311; MolPort-001-785-905; NSC-404118; KB-296111; 12513-EP2316831A1; K572; MolPort-003-719-862; Inositol, chiro-; Inositol (VAN8C; Isoinositol; I14-47230; GTPL4645; s4530; EINECS 211-394-0; 1,2,3,4,5,6-HEXAHYDROXY-CYCLOHEXANE; CHEBI:22357; AK324051; Inositol [USAN:NF]; bmse000922; CDAISMWEOUEBRE-OQYPVSDDSA-N; DSSTox_RID_76890; NCGC00255362-01; 1VS4X81277; 1D-Chiro-inositol; chiro-inositol; BG01505565; 488-55-1; BG01505566; AKOS015960429; NSC103959; 576-63-6; SBI-0051369.P003; 1,2,4,5/3,6-cyclohexanehexol; I14-2742; 12513-EP2277880A1; AKOS015960633; J101.891D; A834712; Scyllitol; CHEBI:23927; KM0846; 1,2,3,4,5,6-Hexahydroxycyclohexane; Spectrum3_001053; HMS2091N13; MLS001332378; MolPort-001-742-552; NCIOpen2_008191; Cocositol; Phaseomannitol; Scyllite; myo-Inositol, 98% 100g; BSPBio_002606; KBio2_002075; FT-0693614; Inositol, United States Pharmacopeia (USP) Reference Standard; TR-017741; CCRIS 6745; STL453612; ZINC253837650; I0631; D03SHD; SCHEMBL6791918; 3635-EP2292088A1; AB00051982_13; CHEBI:17268; TR-022053; Iso-inositol; MFCD00077932; CTK8B3795; myo-Inositol, >=99%; GTPL4495; C19891; KSC225S4P; ZINC100073149; DSSTox_GSID_23146; MLS001335965; TL8004551; SMR000857319; bmse000102; AJ-26654; 887751-76-0; DB03106; UNII-9O6Y5O4P9W; 38876-99-2; myo-Inositol, BioUltra, >=99.5% (HPLC); Inositol, neo-; Matezodambose; 6R79WV4R10; I0040; Mesol; W-203392; NSC404118; 1,2,4/3,5,6-Cyclohexane-1,2,3,4,5,6-hexol; Rat antispectacled eye factor; Inositol FCC; 3635-EP2305682A1; 1,2,3,5/4,6-Cyclohexanehexol; BG01505593; cis-Inositol, >=98.0% (TLC); Tox21_302035; CDAISMWEOUEBRE-LOLGQZEGSA-N; 643-10-7; AKOS027327401; 1,2,4/3,5,6-Hexahydroxycyclohexane; 3635-EP2295417A1; CHEMBL278373; FT-0652045; 3635-EP2305677A1; 1,2,3,4,5,6-Cyclohexanehexol; Neo-inositol; (1s,2R,3R,4s,5S,6S)-cyclohexane-1,2,3,4,5,6-hexol; Q-201583; Hexahydroxycyclohexane; SCHEMBL187278; (1S,2S,4S)-CYCLOHEXANE-1,2,3,4,5,6-HEXOL; CHEMBL1231671; EINECS 207-682-0; I14-47232; 1D-myo-Inositol; CHEMBL468154; SCHEMBL13058696; SC-18136; 3635-EP2280282A1; DB13178; 3635-EP2289886A1; Spectrum_001595; Inositol, Pharmaceutical Secondary Standard; Certified Reference Material; NSC-757076; AKOS006240678; I14-60538; 12513-EP2374790A1; CJ-23964; AK102790; UNII-63GQX5QW03; INS; 87-89-8; Scyllite (for the structural isomer scyllo-Inositol); 2os9; CHEMBL1222251; I14-47231; MLS001335966; (1R,2R,3S,4R,5r,6S)-cyclohexane-1,2,3,4,5,6-hexaol; alloinositol; ANW-43204; 4irx; KS-1420; Inositol (VAN); inositols; 4L6452S749; C06153; (1R,2R,3R,4R,5S,6S)-cyclohexane-1,2,3,4,5,6-hexol; Inosital; ZINC100037751; AB0014290; MEGxp0_001817; (1r,2R,3S,4r,5R,6S)-cyclohexane-1,2,3,4,5,6-hexol; Inositol, myo-; ELND 005; 13719-EP2311831A1; cyclohexane-1,2,3,4,5,6-hexol; FT-0627237; AKOS015912905; KS-0000146H; (+)-Chiro-Inositol; AC1L1A9E; L-(-)-chiro-Inositol, 95%; (1R,2R,3R,4S,5S,6R)-CYCLOHEXANE-1,2,3,4,5,6-HEXOL; myo-Inositol, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture; 3635-EP2305636A1; C06151; 12513-EP2292597A1; myo-Inositol, purum, >=98.0% (HPLC); Inositol, scyllo-; MFCD00799555; 12513-EP2298768A1; NSC-25142; 1,2,3/4,5,6-cyclohexanehexol; MFCD00799556; cis-1,2,4-trans-3,5,6-Cyclohexanehexol; ST24024704; Inositol, myo- (8CI); SCHEMBL13114115; GTPL4649; Bios I; M01914; ST50406013; NSC127230; FT-0632209; ZINC250615063; AC1Q2AJJ; SR-05000001655; Mesoinosite; Muscle sugar; ZINC102201844; 6917-35-7; myo-Inositol, European Pharmacopoeia (EP) Reference Standard; 3635-EP2308879A1; Insitolum; D-myo-Inositol, Cell Culture Grade; I0630; Spectrum4_001193; epi-Cyclohexanehexol; SCHEMBL187796; NSC-45517; CDAISMWEOUEBRE-GPIVLXJGSA-N; 488-54-0; CC-093; 40032-EP2298312A1; ZINC1530357; 13719-EP2308875A1; CHEBI:27987; AN-24133; epi-Inositol; (1r,2R,3R,4s,5S,6S)-cyclohexane-1,2,3,4,5,6-hexol; Pharmakon1600-01500352; CDAISMWEOUEBRE-GNIYUCBRSA-N; Tox21_111642; UNII-6R79WV4R10; 13719-EP2316836A1; SMR000857145; HMS2230N03; (1s,2s,3s,4s,5s,6s)-cyclohexane-1,2,3,4,5,6-hexol; mesoinositol; NCGC00159409-04; CHEBI:27372; CJ-05199; SCHEMBL6378921; AK115152; (1/4) inverted exclamation markIC; SCHEMBL491333; myo-Inositol, Vetec(TM) reagent grade, 99%; 3635-EP2275412A1; ELND005; NCGC00169828-01; I0632; EINECS 207-681-5; 3635-EP2295437A1; SCHEMBL14542470; MolPort-003-848-190; Muco-Inositol; D0Y4UQ; Epi-inositol, 98%; 1,2,3,4,5,6/0-cyclohexanetetrol; Mesovit; D-chiro-Inositol, >=98.0% (HPLC); TRA-0204644; 36190-90-6; NSC 25142; cis-Inositol; (1R,2R,3S,4R)-CYCLOHEXANE-1,2,3,4,5,6-HEXOL; SCHEMBL12377889; cis-1,2,3,5-trans-4,6-Cyclohexanehexol; i-Inositol; L-Inositol; CHEBI:10642; 12513-EP2305825A1; Chiro-inositol, (-)-; Inositol, muco-; Quercinitol; M94176HJ2F; HY-B1411; SCHEMBL12711208; SCHEMBL13580047; CDAISMWEOUEBRE-CDRYSYESSA-N; scyllo-Cyclohexanehexol; ZINC101185827; Allo-inositol; Tox21_111642_1; HMS3373E05; 1,3,5/4,6-Cyclohexanehexol; EINECS 209-000-7; KS-1284; W-203168; 13719-EP2280010A2; Phaseomannite; EPIINOSITOL; (+)-Epi-Inositol; NSC45517; Inositol (NF); 6643AB; (1R,2R,3S,4S,5S,6S)-Cyclohexane-1,2,3,4,5,6-hexaol; SCHEMBL4748543; AK307315; 13719-EP2269977A2; 488-58-4; UNII-M94176HJ2F component CDAISMWEOUEBRE-LKPKBOIGSA-N; cis-1,3,5-trans-4,6-Cyclohexanehexol; SCHEMBL13114128; SCHEMBL6468882; UNII-587A93P465; scyllo-Inositol, >=98%; SMR000857320; D-chiro Inositol; AZD 103; SCHEMBL188237; SCHEMBL12411898; bmse000113; epi-Inositol, >=98.0% (HPLC); MLS001335967; 19030-27-4; AK307406; INOSITOL (L); KBio2_007211; Cyclohexane-1,2,3,4,5,6-hexaol; 41546-34-3; (1S,4S)-CYCLOHEXANE-1,2,3,4,5,6-HEXOL; NSC8101; NSC-55551; 63GQX5QW03; (1R)-Cyclohexane-1r,2c,3t,4c,5t,6t-hexaol; myo -Inositol; ZINC306121118; D08DXZ; ST24049158; AX8234329; Inositol, epi-; TRA0065469; 551-72-4; 488-59-5; NSC55551; 1D7A27BF-6060-4FA9-AC46-3BD18DBA406E; 3635-EP2298312A1; Myoinosite; HMS2235M23; NSC-55552; Inositol [Nonspecific isomer]; A836375; SR-05000001655-5; myo-Inositol, SAJ special grade, >=99.0%; 13719-EP2298734A2; D-chiro-Inositol; HMS2235H05; AN-18118; (1S,2R,4R)-CYCLOHEXANE-1,2,3,4,5,6-HEXOL; KBio3_001826; Inositol, meso-; ZINC103574467; AS-10616; CAS-87-89-8; Inositina; SCHEMBL959404; I0629; BG00909545; AmbotzGBB1246; EINECS 211-393-5; 1,3,5/2,4,6-cyclohexanehexol; EINECS 201-781-2; SCHEMBL5831; Meat sugar; neoinositol; 9O6Y5O4P9W; (-)-chiro-Inositol; 13719-EP2289891A2; AKOS015895894; 13719-EP2295437A1; (-)-Inositol; NSC55552; Cyclohexanehexol; Inosital (TN); Levoinositol; FT-0632208; BG01505583; cyclohexane-1R,2R,3S,4S,5R,6S-hexol; TL8004550; L-chiro-Inositol; Myo inositol; Spectrum5_000961; (1R,2S,3S,4R,5S,6r)-cyclohexane-1,2,3,4,5,6-hexol; myo-inositol; (1S,2R,4S)-CYCLOHEXANE-1,2,3,4,5,6-HEXOL; MFCD00272608; MLS001332377; D08079; SCHEMBL12371461; meso-Inositol; D-myo-Inositol; Cyclohexitol; ZINC100018867; 1,2,3,4/5,6-cyclohexanehexol; D-(+)-chiro-Inositol, 95%; (1R,2R,3S,4S,5S,6S)-cyclohexane-1,2,3,4,5,6-hexol; ACon1_002457; KBioGR_001885; NSC-8101; TR-019452; FT-0670357; AKOS015994742; ZINC100032893; NSC757076; CS-4782; allo-Inositol, 97%; AN-23658; Mesoinosit; KS-00000QA9; AKOS027320475; KBio2_004643; ZINC103574475; UNII-4L6452S749; SCHEMBL5969; ZINC100055570; 1,3,5/2,4,6-Hexahydroxycyclohexane; KS-000017FC; 3635-EP2298775A1; bmse000901; FCH1118762; NCGC00159409-03; R1Y9F3N15A; I14-101844; myo-Inositol, for microbiology, >=99.0%; I0633; Dambose; myo-Inositol, PharmaGrade, meets FCC testing specifications, Manufactured under appropriate controls for use as a raw material in pharma or biopharmaceutical production.; FT-0693444; 1-L-chiro-Inositol; (1r,2r,3r,4r,5r,6r)-cyclohexane-1,2,3,4,5,6-hexol; SR-05000001655-1; SCHEMBL188106; L-(-)-chiro-Inositol; L-myo-Inositol; 1,2,3,4,5,6-Cyclohexanehexaol; UNII-M94176HJ2F component CDAISMWEOUEBRE-SHFUYGGZSA-N; ZINC100513675; 173524-45-3; 643C129; NSC-55558; CCG-36096; Mouse antialopecia factor; FT-0632730; NSC55558; 8LQ63P85IC; I0628; MolPort-006-111-433; NCI60_041778; CDAISMWEOUEBRE-NIPYSYMMSA-N; KBioSS_002075; C00137; CBU; 220128F1-89BF-442D-AD6D-E6D1EA7BA625; UNII-R1Y9F3N15A; D0B1EY; 1,2,3,5-trans-4,6-Cyclohexanehexol, cis-; MolPort-003-933-930; 587A93P465; CHEBI:25492; NSC 404118; UNII-M94176HJ2F; MCULE-2727773046; J101.890F; HMS3369F20; SCHEMBL5832; UNII-8LQ63P85IC; 12513-EP2277881A1; UNII-4661D3JP8D; 53319-35-0; MLS001335968; 1,2,3,4,5,6-Cyclohexanehexol #; myo-Inositol, p.a., 98.0%; meso-(1/4) inverted exclamation mark (1/4); AC-11070; SCHEMBL959405; NCGC00178580-03; (1r,2R,3S,4s,5R,6S)-cyclohexane-1,2,3,4,5,6-hexol; I06-1350; 1L-Chiro-inositol; SCHEMBL1055883; Nucite; LS-2350; RP24128; 1,2,3,4,5/6-cyclohexanehexol; GTPL4648; Epitope ID:144993; SCHEMBL12735687; AKOS006332036; Inositol NF 12; MFCD00003863; AK546883; 1,2,4/3,5,6-cyclohexanehexol; 13719-EP2298775A1; EINECS 230-024-9; W-202862; (1R,2R,3S,4S,5S,6R)-CYCLOHEXANE-1,2,3,4,5,6-HEXOL; NCGC00159409-02; 4661D3JP8D; 1L-myo-Inositol; Scyllo-inositol; C06152; Chiro-inositol, (+)-; Inositol, i-; CHEMBL1950780; 1,2,3,4,5,6-cyclohexanhexol; 1,2,3,4,5,6-cyclohexanehexol, (1alpha,2alpha,3alpha,4beta,5alpha,6beta); D-(+)-Chiro Inositol; SC-91157; KS-00001315; NP-010162; I14-47229; VC30505; 4CH-024633; KB-251247; MFCD00065455; (1R,2R,3S,4R,5S,6S)-cyclohexane-1,2,3,4,5,6-hexol; CDAISMWEOUEBRE-UHFFFAOYSA-N; ZINC100024490; Inositol, allo-; AI3-16111; Ambap6917-35-7; HMS3369B06; 7B0CEF84-D9CE-4A88-AA7D-EC50C89387A5; 1,3,4,5,6-Cyclohexanehexol; inositol; W-202861; SCHEMBL187397; DSSTox_CID_3146; ZINC100035580; 40032-EP2311830A1; 12513-EP2298744A2; K-9876; INOSITOL, MESO; CHEBI:24848; bmse000103; TR-016439; SCHEMBL13207905; (+)-Inositol; CHEMBL122705;cocositol;D-myo-inositol | C6H12O6 | 180.16 g/mol | C1(C(C(C(C(C1O)O)O)O)O)O |
| TCMBANKIN058450 | ADO | nchembio.2007.56-comp13; CHEBI:16335; Bio1_000437; 9-beta-D-Ribofuranosyl-9H-purin-6-amine; AIDS-001224; 9beta-D-Ribofuranosyladenine; BSPBio_001796; beta-Adenosine; (2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-methylol-tetrahydrofuran-3,4-diol; beta-D-Ribofuranoside, adenine-9; D00045; 46969-16-8; SDCCGMLS-0003108.P003; 4-Aminopyrazolo[3,4-d]pyrimidine ribonucleoside; (2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; 6-Amino-9-.beta.-ribofuranosyl-9H-purine; NSC 7652; Bio1_001415; Adenosine (JAN/USP); Spectrum2_001257; Spectrum3_000288; Adenosine, homopolymer; ADN; Caswell No. 010B; Adenocard; C00212; SR 96225; Adenocard (TN); EINECS 200-389-9; KBio3_001296; 9H-Purin-6-amine, 9beta-D-ribofuranosyl-; Polyadenosine; beta-D-Ribofuranose, 1-(6-amino-9H-purin-9-yl)-1-deoxy-; (2R,3R,4S,5R)-2-(6-amino-9-purinyl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol; MLS000069638; AI3-52413; 9-beta-D-Ribofuranosidoadenine; A9251_SIGMA; Adenoscan (TN); Bio1_000926; ZINC02169830; CCRIS 2557; NCGC00023673-05; Ade-Rib; nchembio706-5; 30143-02-3; 6-Amino-9-beta-D-ribofuranosyl-9H-purine; Adenosin [German]; NSC 627048; SMR000058216; 9-beta-D-Ribofuranosyladenine; SPBio_001194; beta-D-Adenosine; Adenosine [USAN:BAN]; Polyriboadenosine; (2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol; AIDS001224; 6-Amino-9beta-D-ribofuranosyl-9H-purine; ST009496; Adenoscan; A4036_SIGMA; SPECTRUM1500107; 46946-45-6;SCHEMBL170902; adenosine ; AKOS015960342; AC-5504; BC200893; Adenosine;adenosine;adeninenucleoside | C10H13N5O4 | 267.24 g/mol | C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N |
| TCMBANKIN058836 | (5Z,9Z)-6,10,14-trimethylpentadeca-5,9,13-trien-2-one | hydrofarnesylacetone; (5E,9E)-farnesyl acetone; farnesylacetone; CHEBI:67252; FEMA No. 3442; Farnesylacetone; trans, trans-farnesylacetone; DTXSID5061087; EINECS 212-097-9; AC1LVUAM; 6,10,14-Trimethyl-5,9,13-pentadecatrien-2-one; AN-20576; (E,E)-6,10,14-Trimethylpentadeca-5,9,13-trien-2-one; 3S0G4N267H; farnesylacetol; ST24026309; Pentadeca-5,9,13-triene-2-one, 6,10,14-trimethyl-; 46195_FLUKA; SCHEMBL17273769; SBB012619; AJ-61341; UNII-3S0G4N267H; 762-29-8; 36115P; Farnesyl acetone; 5,9,13-Pentadecatriene-2-one, 6,10,14-trimethyl-; LTUMRKDLVGQMJU-UHFFFAOYSA-N; LTUMRKDLVGQMJU-IUBLYSDUSA-N; EINECS 214-246-3; AK112408; 117F528; 5,9,13-Pentadecatrien-2-one, 6,10,14-trimethhyl-, [E,E]; AKOS015963256; Farnesylacetone, technical, mixture of stereo isomers, >=90% (GC); S408; Farnesyl acetone, (5E,9E)-; 6,10,14-Trimethylpentadeca-5,9,13-trien-2-one; 5,9,13-Pentadecatrien-2-one, 6,10,14-trimethyl-, (E,E)-; (5E,9E)-6,10,14-Trimethyl-5,9,13-pentadecatrien-2-one; (5E,9E)-6,10,14-trimethylpentadeca-5,9,13-trien-2-one; E,E-farnesylacetone; 5,9,13-Pentadecatrien-2-one, 6,10,14-trimethyl-, (5E,9E)-; 1117-52-8; ZERO/001267; Farnesylacetone, mixture of isomers; trans,trans-farnesylacetone; 5,9,13-PENTADECATRIEN-2-ONE, 6,10,14-TRIMETHYL-; AC1Q1K55; MolPort-005-306-293; MFCD00036517; ZINC12358879; KB-208683; farnesyl acetone; 2,6,10-Trimethyl-2,6,10-pentadecatrien-14-one; UNII-26A08O86E6 component LTUMRKDLVGQMJU-IUBLYSDUSA-N; (E,E)-farnesylacetone; CHEMBL486207; TRIMETHYLPENTADECATRIEN-2-ONE; MCULE-4966055907; I14-113745; Famesyl acetone; (5E,9E)-6,10,14-Trimethyl-5,9,13-pentadecatrien-2-one #; e,e-farnesylacetone; (E, E)- farnesyl acetone; Famesyl acetone | C18H30O | 262.4 g/mol | CC(=CCCC(=CCCC(=CCCC(=O)C)C)C)C |
| TCMBANKIN058958 | LEVA | gamma-Ketovaleric acid; .gamma.-Ketovaleric acid; 3-Acetylpropionsaeure; Levulinsaeure; InChI=1/C5H8O3/c1-4(6)2-3-5(7)8/h2-3H2,1H3,(H,7,8; Valeric acid, 4-oxo-; 4-03-00-01560 (Beilstein Handbook Reference); NSC3716; CHEBI:45630; .beta.-Acetylpropionic acid; AIDS017682; LMFA01060006; AI3-03377; ST5213942; 3-Ketobutane-1-carboxylic acid; Laevulinic acid; 4-Ketovaleric acid; 4-Oxopentanoic acid; 4-Oxovaleric acid; WLN: QV2V1; NSC 3716; Usaf cz-1; Acidum laevulinicum; PENTANOIC ACID,4-OXO MFC5 H8 O3; 3-Acetylpropionic acid; 4-Oxopentansaeure; Pentanoic acid, 4-oxo; Propionic acid, 3-acetyl-; BRN 0506796; EINECS 204-649-2; beta-Acetylpropionic acid; 4-oxo-pentanoic acid; 123-76-2; Pentanoic acid, 4-oxo-; Laevulic acid; Acetopropionic acid; Levulinic acid; VALERIC ACID, 4-OXO-(LEVULINIC ACID); Levulic acid; Laevulinsaeure; FEMA No. 2627; AIDS-017682; levulinic acid; 4-oxopentanoic acid | C5H8O3 | 116.12 g/mol | CC(=O)CCC(=O)O |
| TCMBANKIN059062 | acetoin | (3S)-3-oxidanylbutan-2-one; A828564; AC1L9L7E; 1p28; (+)-acetoin; R,3-HYDROXYBUTAN-2-ONE; 78183-56-9; CTK2G5620; (3S)-3-hydroxy-2-butanone; (S)-Acetoin; HBS; S,3-HYDROXYBUTAN-2-ONE; (3S)-3-hydroxybutan-2-one; (S)-acetylmethylcarbinol; AJ-24161; (S)-2-Acetoin; UNII-BG4D34CO2H component ROWKJAVDOGWPAT-VKHMYHEASA-N; L-(+)-acetoin; ZINC895238; 2-Butanone, 3-hydroxy-, (3S)-; C01769; CHEBI:15687; DB02788;3-hydroxy-2-butanone;Acetyl methyl carbinol;3-Hydroxybutan-2-One | C4H8O2 | 88.11 g/mol | CC(C(=O)C)O |
| TCMBANKIN059288 | horhammericine | C21H24N2O4 | 368.4 g/mol | CC(C12CC(=C3C4(C1N(CC4)CC5C2O5)C6=CC=CC=C6N3)C(=O)OC)O | |
| TCMBANKIN059314 | 3,4-di-o-caffeoyl-5-o-(3-hydroxy-3-methyl)glutaroyl quinicacid | 3,4-dicaffeoyl-5-(3-hydroxy-3-methyl) glutaroyl quinic acid;3,4-dicaffeoyl-5-(3-hydroxy-3-methyl)glutaroyl quinic acid; (1S)-3-(3,5-dihydroxy-3-methyl-5-oxopentanoyl)oxy-4,5-bis[[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]-1-hydroxycyclohexane-1-carboxylic acid; AC1NSUGR | C31H32O16 | CC(CC(=O)O)(CC(=O)OC1CC(CC(C1OC(=O)C=CC2=CC(=C(C=C2)O)O)OC(=O)C=CC3=CC(=C(C=C3)O)O)(C(=O)O)O)O | |
| TCMBANKIN059416 | vincarine | C21H24N2O3 | 352.4 g/mol | CC=C1CN2C3CC1C4(C2CC5(C3NC6=CC=CC=C65)C4O)C(=O)OC | |
| TCMBANKIN059417 | pericalline | C18H20N2 | 264.4 g/mol | CC=C1CN2CCC1C(=C)C3=C(C2)C=C4C=CNC4=C3 | |
| TCMBANKIN059557 | triacetonamine | C9H17NO | 155.24 g/mol | CC1(CC(=O)CC(N1)(C)C)C | |
| TCMBANKIN059885 | (6s,9r)-roseoside | C19H30O8 | 386.4 g/mol | CC1=CC(=O)CC(C1(C=CC(C)OC2C(C(C(C(O2)CO)O)O)O)O)(C)C | |
| TCMBANKIN060045 | Skatol | C9H9N | 131.17 | CC1=CNC2=CC=CC=C12 | |
| TCMBANKIN060263 | syringetin-3-rutinoside | C29H34O17 | 654.57 | CC1C(C(C(C(O1)OCC2C(C(C(C(O2)OC3=C(OC4=CC(=CC(=C4C3=O)O)O)C5=CC(=C(C(=C5)OC)O)OC)O)O)O)O)O)O | |
| TCMBANKIN060340 | vindolinine | C21H24N2O2 | 336.4 g/mol | CC1C23CC(C14C5(C2N(CC5)CC=C3)C6=CC=CC=C6N4)C(=O)OC | |
| TCMBANKIN060421 | gomisin | C30H32O9 | 536.6 g/mol | CC1CC2=CC3=C(C(=C2C4=C(C(=C(C=C4C(C1(C)O)OC(=O)C5=CC=CC=C5)OC)OC)OC)OC)OCO3 | |
| TCMBANKIN060725 | vincaleukoblastine;vinblastine;leurosidine;vincovalinine | C46H58N4O9 | 810.97 g/mol | CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O | |
| TCMBANKIN060742 | catharosine | C22H28N2O4 | 384.5 g/mol | CCC12C=CCN3C1C4(CC3)C(C(C2O)(C(=O)OC)O)N(C5=CC=CC=C45)C | |
| TCMBANKIN060743 | lochnerinine | C22H26N2O4 | 382.5 g/mol | CCC12CC(=C3C4(C1N(CC4)CC5C2O5)C6=C(N3)C=C(C=C6)OC)C(=O)OC | |
| TCMBANKIN060744 | lochnercine | C21H24N2O3 | 352.4 g/mol | CCC12CC(=C3C4(C1N(CC4)CC5C2O5)C6=CC=CC=C6N3)C(=O)OC | |
| TCMBANKIN061232 | pseudoaconitine | C36H51NO12 | 689.8 g/mol | CCN1CC2(C(CC(C34C2C(C(C31)C5(CC(C6(CC4C5C6OC(=O)C7=CC(=C(C=C7)OC)OC)O)OC)OC(=O)C)OC)OC)O)COC | |
| TCMBANKIN061351 | Insularine | insularine; UNII-60I96OKL0W; O-Methylinsulanoline; 60I96OKL0W; 549-07-5; 6,9-(Epoxymethano)-8,11:20,23-dietheno-1H,12H-(1,10)dioxacyclooctadecino(2,3,4-ij:11,12,13-i'j')diisoquinoline, 2,3,12a,13,14,15,24,24a-octahydro-5,17,18-trimethoxy-1,13-dimethyl-, (12aR,24aR)-; Insularine [MI] | C38H40N2O6 | 620.7 g/mol | CN1CCC2=CC(=C3C4=C2C1CC5=CC=C(C=C5)OC6=C7C(CC8=CC(=C(O4)C=C8)CO3)N(CCC7=CC(=C6OC)OC)C)OC |
| TCMBANKIN061443 | swertiajaponin | 2-(3,4-dihydroxyphenyl)-5-hydroxy-7-methoxy-6-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-2-tetrahydropyranyl]-4-chromenone; 2-(3,4-dihydroxyphenyl)-5-hydroxy-7-methoxy-6-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]chromen-4-one; 4H-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-6-beta-D-glucopyranosyl-5-hydroxy-7-methoxy-; Swertiajaponin; 2-(3,4-dihydroxyphenyl)-5-hydroxy-7-methoxy-6-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]chromen-4-one; C10187; 2-(3,4-dihydroxyphenyl)-5-hydroxy-7-methoxy-6-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-methylol-tetrahydropyran-2-yl]chromone; 6980-25-2;LMPK12111030; 6-beta-D-glucopyranosyl-3',4',5-trihydroxy-7-methoxyflavone; SCHEMBL4783740; Swertiajaponin; Leucanthoside;Leucanthoside;5,7,4'- trihydroxy- 6-methoxyflavone | C22H22O11 | 462.4 g/mol | COC1=C(C(=C2C(=C1)OC(=CC2=O)C3=CC(=C(C=C3)O)O)O)C4C(C(C(C(O4)CO)O)O)O |
| TCMBANKIN061953 | Mallow pigment | Rose oxides; Zinc oxide | ZnO or OZn | 81.4 g/mol | O=[Zn] |
植物对应的疾病
| 疾病ID | 病名 | 疾病类型 | MeSH | 参考文献 |
|---|
植物对应的靶点
| 靶点ID | 基因名 | 基因别名 | 描述 | 染色体位置 | Map_Location | 基因类型 |
|---|
滇ICP备16009434号-1 |
Dai SX Lab